Insulin Delivery Devices

Stewart, Kristine M.; Wilson, M.; Rider, Joan M.

doi:10.1177/0897190003261305

Cited by 16 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When using a traditional syringe system, the lubrication material is often removed when inserting the needle through the insulin cartridge rubber stopper, creating a more painful injection experience. 15 The NovoPen family uses NovoFine, NovoFine Plus, and NovoTwist needles, which are specifically designed to address usability and patient comfort. 5 , 7 , 8 NovoFine needles have two caps: an outer needle cap and a second inner needle cap that also covers the needle.…”

Section: Methods Of Insulin Delivery and Patient Usementioning

confidence: 99%

“…Unpredictable lifestyles, irregular eating patterns, pain upon injection, and the social stigma associated with injecting in public are the factors that make adhering to a particular treatment regimen challenging. 12 – 15 Children and adolescents also require a lower and more accurate dose of insulin to maintain good glycemic control due to their smaller body size. It is important for older children to begin to take responsibility for calculating doses and preparing devices for injection without appropriate guidance from parents and caregivers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

NovoPen Echo® insulin delivery device

Hyllested‐Winge¹,

Sparre²,

Pedersen³

2016

MDER

View full text Add to dashboard Cite

The introduction of insulin pen devices has provided easier, well-tolerated, and more convenient treatment regimens for patients with diabetes mellitus. When compared with vial and syringe regimens, insulin pens offer a greater clinical efficacy, improved quality of life, and increased dosing accuracy, particularly at low doses. The portable and discreet nature of pen devices reduces the burden on the patient, facilitates adherence, and subsequently contributes to the improvement in glycemic control. NovoPen Echo® is one of the latest members of the NovoPen® family that has been specifically designed for the pediatric population and is the first to combine half-unit increment (=0.5 U of insulin) dosing with a simple memory function. The half-unit increment dosing amendments and accurate injection of 0.5 U of insulin are particularly beneficial for children (and insulin-sensitive adults/elders), who often require small insulin doses. The memory function can be used to record the time and amount of the last dose, reducing the fear of double dosing or missing a dose. The memory function also provides parents with extra confidence and security that their child is taking insulin at the correct doses and times. NovoPen Echo is a lightweight, durable insulin delivery pen; it is available in two different colors, which may help to distinguish between different types of insulin, providing more confidence for both users and caregivers. Studies have demonstrated a high level of patient satisfaction, with 80% of users preferring NovoPen Echo to other pediatric insulin pens.

show abstract

Section: Methods Of Insulin Delivery and Patient Usementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

NovoPen Echo® insulin delivery device

Hyllested‐Winge¹,

Sparre²,

Pedersen³

2016

MDER

View full text Add to dashboard Cite

show abstract

“…The method by which insulin is administered has been shown to impact patient acceptability of insulin therapy and quality of life, and may serve as a key barrier to insulin initiation [20]. Previously, the predominant route of insulin administration for patients with diabetes was the syringe and vial.…”

Section: Insulin Administrationmentioning

confidence: 99%

Insulin glargine and glulisine SoloSTAR^®pens for the treatment of diabetes

Garg

Kelly

Garg

2008

Expert Review of Medical Devices

View full text Add to dashboard Cite

Insulin is an effective medication for lowering hemoglobin A(1c) values and can be used for both basal and prandial coverage of hyperglycemia in Type 1 and Type 2 diabetes. Despite its effectiveness there is still reluctance by patients and physicians to add insulin into the treatment regimen for Type 2 diabetes when needed. One of the key barriers to initiating insulin therapy is the method of delivery. Insulin delivery pens are continually developed as a means to improve upon the vial and syringe and to make it easier for patients to incorporate insulin therapy into their lifestyles. The SoloSTAR pen (Sanofi-Aventis, Paris, France) was developed to make insulin delivery easier and to help eliminate barriers to the initiation of insulin therapy. In this article, we discuss the features and characteristics of SoloSTAR that overcome existing unmet needs.

show abstract

“…Согласно данным большинства сравнительных исследований, значительных различий уровня гликированного гемоглобина с учетом разных режимов инсулинотерапии, в том числе при сравнении инъекционных систем НовоПен ® с инсулиновыми шприцами и носимыми дозаторами инсулина, не отмечено [2,3,4]. Вместе с этим в ряде исследований, где пациентов с неудовлетворительным контролем заболевания на традиционной инсулинотерапии переводили на интенсифицированный режим инсулинотерапии с использованием инъекционных систем НовоПен ® , отмечалось значительное снижение уровня гликированного гемоглобина, особенно в группе пациентов с исходным показателем НbА 1с >9% [5,6].…”

Section: /2011unclassified